C. Masset

Sickle cell disease and COVID‐19: Atypical presentations and favorable outcomes

J. Thachil, H. Deckmyn, Y. Beguin, 2020, EJHaem.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Physiological response from 18-25 years women to aerobic and anaerobic physical fitness tests at different periods during the menstrual cycle.

X. Sturbois, C. Masset, P. de Bruyn-Prévost, 1984, The Journal of sports medicine and physical fitness.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.